Tadalafil is the active drug ingredient in Adcirca, while Adcirca is a specific branded tablet product built around the pulmonary arterial hypertension treatment context. Current U.S. labeling identifies Adcirca as tadalafil tablets and indicates the product for PAH, WHO Group 1, to improve exercise ability.
The relationship is similar to other drug-and-brand relationships: the molecule supplies the pharmacology, while the brand identifies a particular finished product and its approved labeling. Adcirca tablets contain 20 mg tadalafil, and the standard PAH framework uses 40 mg once daily, taken as two 20 mg tablets rather than as an ED-style regimen.
This distinction matters because tadalafil also appears in Cialis and generic ED/BPH tablet products. Sharing tadalafil does not make those products interchangeable with Adcirca or give every tadalafil product the same indication and instructions. Detailed Adcirca product information belongs on Adcirca, while this page focuses specifically on the identity relationship between tadalafil and the Adcirca brand.
The cleanest way to understand Adcirca is to separate four layers: the active ingredient, the finished brand product, the approved indication and the treatment framework. Tadalafil identifies the drug substance, while Adcirca identifies one specific tadalafil-containing PAH product.
The table below captures that relationship without turning the page into a complete Adcirca monograph.
| Brand-Context Feature | Adcirca |
|---|---|
| Active ingredient | Tadalafil |
| Drug class | PDE5 inhibitor |
| Dosage form | Oral tablet |
| Tablet strength | 20 mg tadalafil |
| Labeled indication | Pulmonary arterial hypertension, WHO Group 1 |
| Labeled treatment objective | Improve exercise ability |
| Standard treatment framework | 40 mg once daily |
| How the standard dose is supplied | Two 20 mg tablets taken together |
Yes in the active-ingredient sense: Adcirca contains tadalafil as its pharmacologically active drug. The terms are not identical product names, however, because tadalafil identifies the active molecule whereas Adcirca identifies a specific branded finished product.
A precise statement is therefore that Adcirca is a tadalafil product, not that tadalafil and Adcirca are interchangeable names for every possible tadalafil medicine.
| Statement | Accurate? |
|---|---|
| Adcirca contains tadalafil | Yes |
| Tadalafil is the active ingredient in Adcirca | Yes |
| Tadalafil and Adcirca are unrelated drugs | No |
| Every tadalafil product is Adcirca | No |
| Adcirca is one branded tadalafil product | Yes |
Drug identity and product identity answer different questions. Tadalafil tells you which molecule is producing the pharmacologic effect, while Adcirca tells you which branded product and prescribing framework are being discussed.
This distinction becomes important whenever the same active ingredient appears under more than one brand or indication. Tadalafil does exactly that, appearing in both PAH and ED/BPH product contexts.
| Identity Layer | Adcirca Example |
|---|---|
| Active drug | Tadalafil |
| Brand | Adcirca |
| Drug class | PDE5 inhibitor |
| Disease context | PAH |
| Finished-product instructions | Defined by the Adcirca label |
Current U.S. prescribing information identifies the product as ADCIRCA (tadalafil) tablets. That naming format places the proprietary brand name next to the established drug name so both the finished product and its active ingredient are clear.
The parentheses do not describe two active drugs. They identify one branded product containing tadalafil.
| Label Term | Meaning |
|---|---|
| ADCIRCA | Proprietary brand name |
| tadalafil | Established active-drug name |
| ADCIRCA (tadalafil) tablets | Brand product linked to its active ingredient and dosage form |
Adcirca's current U.S. indication is pulmonary arterial hypertension, WHO Group 1, to improve exercise ability. Its product labeling and clinical-development framework are therefore centered on pulmonary vascular disease rather than erectile dysfunction or BPH.
This is why a search for 'tadalafil Adcirca' leads to a different clinical context from a search for tadalafil and Cialis. The PAH indication itself is covered in depth on Tadalafil for Pulmonary Hypertension.
| Adcirca Label Question | Answer |
|---|---|
| Primary labeled condition | Pulmonary arterial hypertension |
| WHO classification | WHO Group 1 |
| Labeled objective | Improve exercise ability |
| ED listed as the Adcirca indication | No |
| BPH listed as the Adcirca indication | No |
Adcirca's tablet strength and its standard total daily PAH dose are different pieces of information. Each Adcirca tablet contains 20 mg tadalafil, while current labeling recommends 40 mg once daily in the standard PAH framework, meaning two 20 mg tablets are taken together.
This distinction prevents a common terminology error: Adcirca is not simply a single '40 mg tablet.' The 40 mg figure describes the standard daily amount in the PAH regimen, while 20 mg describes the strength of each tablet.
| Term | Adcirca Context |
|---|---|
| Tablet strength | 20 mg tadalafil |
| Standard PAH daily amount | 40 mg |
| Number of 20 mg tablets in that amount | Two |
| Frequency | Once daily |
| Dose divided across the day | Not recommended in current labeling |
The number of milligrams identifies the amount of active tadalafil in a dosage unit; it does not by itself establish which branded or generic product has been supplied. Other tadalafil tablet products can also contain 20 mg of the same active ingredient.
Brand identity therefore requires the actual product name, manufacturer or label context rather than inference from strength alone. This is one reason tadalafil and Adcirca should not be used as universal synonyms.
| Information | What It Tells You |
|---|---|
| Tadalafil | Active drug |
| 20 mg | Amount of tadalafil in the dosage unit |
| Adcirca 20 mg | Specific branded tadalafil tablet product and strength |
| 20 mg alone | Does not establish Adcirca brand identity |
Adcirca and Cialis both contain tadalafil, so the underlying active molecule is the same. Their product identities are different because Adcirca is labeled for PAH, while current U.S. Cialis labeling covers ED, BPH and combined ED/BPH.
This page uses that contrast only to clarify identity. Detailed brand-to-brand comparison belongs on Cialis vs Adcirca.
| Feature | Adcirca | Cialis |
|---|---|---|
| Active ingredient | Tadalafil | Tadalafil |
| Brand identity | Adcirca | Cialis |
| Primary U.S. label context | PAH | ED / BPH / ED+BPH |
| Same finished product | No | No |
A drug molecule can have clinical evidence and approved use in more than one disease context. Tadalafil illustrates this clearly because PDE5 inhibition is relevant in pulmonary vascular smooth muscle as well as tissues involved in other tadalafil indications.
Regulatory approval still attaches uses and instructions to specific products. The fact that tadalafil has more than one clinical application does not automatically transfer every indication from one tadalafil product label to another.
| Shared Across Tadalafil Products | Can Differ by Product |
|---|---|
| Active tadalafil molecule | Indication |
| PDE5-inhibiting pharmacology | Strength presentation |
| Core active-drug interaction principles | Dosage form |
| Core molecule identity | Treatment framework |
| Tadalafil pharmacologic class | Product-specific instructions |
Tadalafil appears in multiple finished products. Cialis and many generic tadalafil tablets exist in ED/BPH treatment contexts, while Adcirca belongs to PAH and Tadliq provides another tadalafil-containing PAH product in oral-suspension form.
Using Adcirca as a generic name for all tadalafil would therefore be incorrect. The broad product map is covered on Tadalafil Brand Names and Tadalafil Uses.
| Product Context | Contains Tadalafil? | Literally Adcirca? |
|---|---|---|
| Adcirca | Yes | Yes |
| Cialis | Yes | No |
| Generic tadalafil ED/BPH tablets | Yes | No |
| Tadliq | Yes | No |
Adcirca is not the only tadalafil-containing PAH product context. Tadliq contains tadalafil as a 20 mg/5 mL oral suspension and is also labeled for WHO Group 1 PAH to improve exercise ability.
Tadliq is not Adcirca in liquid form as a matter of product identity; it is a separate finished product with its own dosage form and labeling. The dedicated product page is Tadliq.
| Feature | Adcirca | Tadliq |
|---|---|---|
| Active ingredient | Tadalafil | Tadalafil |
| Dosage form | Tablet | Oral suspension |
| PAH indication | Yes | Yes |
| Same finished product | No | No |
The PDE5-inhibiting activity of Adcirca is produced by tadalafil rather than by the brand name itself. In pulmonary vascular smooth muscle, PDE5 inhibition reduces cGMP degradation and supports vasodilation within the PAH pharmacologic context.
That molecular mechanism belongs to tadalafil and can therefore be discussed independently of the Adcirca brand. Detailed pharmacology is covered on Tadalafil PDE5 Inhibition and Tadalafil Pharmacodynamics.
| Pharmacology Layer | Identity |
|---|---|
| Active molecule | Tadalafil |
| Primary target | PDE5 |
| PAH tissue context | Pulmonary vascular smooth muscle |
| Brand name creates a different molecular mechanism | No |
Tadalafil in Adcirca is not a special PAH-only molecular version of tadalafil. The therapeutic context changes because the finished product, evidence base and approved labeling differ, not because the tadalafil molecule has acquired a different chemical identity.
This is an important distinction when interpreting brand names. Product labels can differ substantially while the active pharmaceutical ingredient remains the same.
| Question | Answer |
|---|---|
| Is Adcirca's active ingredient tadalafil? | Yes |
| Is it a chemically different tadalafil molecule from Cialis? | No |
| Can the label context still be different? | Yes |
| Can treatment instructions therefore differ? | Yes |
Knowing that a product contains tadalafil identifies its active drug but does not provide the complete prescribing context. The Adcirca label connects tadalafil to WHO Group 1 PAH, a 20 mg tablet presentation and a standard 40 mg once-daily framework.
That information cannot be reconstructed safely by copying instructions from a different tadalafil brand. For broader dose architecture across tadalafil products, see Tadalafil Dosage.
| Information Layer | Question It Answers |
|---|---|
| Active ingredient | What drug is present? |
| Brand | Which finished product is being discussed? |
| Indication | What is the product labeled to treat? |
| Strength | How much drug is in each dosage unit? |
| Regimen | How is that product used in its label context? |
Because Adcirca contains tadalafil, core tadalafil pharmacology and contraindications remain relevant. Current Adcirca labeling contraindicates organic nitrates and guanylate-cyclase stimulators such as riociguat because of the risk of excessive hypotensive effects.
Brand recognition therefore does not replace active-ingredient recognition. Someone reviewing an interaction needs to recognize Adcirca as tadalafil rather than treating the brand name as an unrelated medicine.
Detailed safety topics belong on Tadalafil Contraindications and Tadalafil Drug Interactions.
| Safety Identity Point | Meaning |
|---|---|
| Adcirca contains tadalafil | Tadalafil interaction principles apply |
| Organic nitrates | Contraindicated |
| Riociguat / GC stimulators | Contraindicated |
| Different brand name removes active-drug interactions | No |
Because both Adcirca and Cialis contain tadalafil, taking the two together would not represent exposure to two unrelated active ingredients. Current Adcirca labeling advises avoiding concomitant use with Cialis or other PDE5 inhibitors.
This is a practical example of why active-ingredient identity matters. Brand names can differ while pharmacologic duplication remains present.
| Combination | Identity Interpretation |
|---|---|
| Adcirca + Cialis | Two brands involving the same active tadalafil molecule |
| Adcirca + another PDE5 inhibitor | Overlapping PDE5-inhibitor pharmacology |
| Current Adcirca label approach | Avoid concomitant use |
The purpose of this page is to explain how tadalafil and Adcirca relate: tadalafil is the active drug, and Adcirca is a PAH-labeled brand containing it. That relationship can be understood without ranking Adcirca against Cialis or asking which product is 'stronger.'
A direct brand comparison requires a different framework because indication, dose structure and product purpose differ. That intent belongs on Cialis vs Adcirca.
| Question | Best Page |
|---|---|
| How are tadalafil and Adcirca related? | This page |
| What is Adcirca as a branded product? | Adcirca |
| How do Cialis and Adcirca differ? | Cialis vs Adcirca |
| How is tadalafil used for PAH? | Tadalafil for Pulmonary Hypertension |
A relationship page only needs enough product detail to establish why the Adcirca name matters. Questions about exact packaging, storage, product presentation, manufacturer-specific details and complete prescribing information concern Adcirca as a finished pharmaceutical product rather than the meaning of the tadalafil-Adcirca relationship.
Those details belong on the dedicated Adcirca product page. Keeping that boundary prevents two pages from competing for the same brand-product intent.
| Topic | Owner |
|---|---|
| Tadalafil = active ingredient in Adcirca | This page |
| Why Adcirca is a PAH tadalafil brand | This page |
| Full Adcirca product profile | Adcirca |
| Cialis vs Adcirca comparison | Cialis vs Adcirca |
Most confusion comes from treating the active molecule, tablet strength, daily dose and brand name as though they were the same type of information. They are separate layers: tadalafil is the drug, Adcirca is the brand, 20 mg is the tablet strength and 40 mg once daily is the standard PAH regimen.
Keeping those layers separate also prevents Adcirca from being mistaken for Cialis or from becoming a generic name for every tadalafil product.
| Misunderstanding | More Accurate Interpretation |
|---|---|
| "Adcirca and tadalafil are unrelated drugs" | No; tadalafil is the active ingredient in Adcirca. |
| "Every tadalafil product is Adcirca" | No; Adcirca is one branded tadalafil product. |
| "Adcirca is a 40 mg tablet" | Current Adcirca tablets contain 20 mg; the standard PAH regimen totals 40 mg using two tablets. |
| "Any tadalafil 20 mg tablet is Adcirca" | No; strength alone does not establish brand identity. |
| "Adcirca is simply another name for Cialis" | No; both contain tadalafil but are different brand and label contexts. |
| "Adcirca is used as needed like ED tadalafil" | No; its PAH framework is once daily. |
| "Adcirca and Cialis can be treated as unrelated active drugs" | No; both contain tadalafil. |
Adcirca contains tadalafil as its active ingredient. Tadalafil is the drug name, while Adcirca is a specific branded tadalafil tablet product.
The active ingredient in Adcirca is tadalafil, a phosphodiesterase type 5, or PDE5, inhibitor.
Current U.S. Adcirca labeling indicates the product for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
Current U.S. Adcirca tablets contain 20 mg tadalafil per tablet.
No. Each Adcirca tablet contains 20 mg tadalafil. The standard labeled PAH regimen totals 40 mg once daily by using two 20 mg tablets.
The current standard PAH dose is 40 mg once daily, while each Adcirca tablet contains 20 mg tadalafil. Two 20 mg tablets therefore provide the standard 40 mg total daily amount.
Current Adcirca labeling states that dividing the 40 mg dose over the course of the day is not recommended.
No. Both products contain tadalafil, but Adcirca is a PAH-labeled brand while current U.S. Cialis labeling covers ED, BPH and combined ED/BPH.
No. Tadalafil is the active drug in both products. The differences are in product identity, indication and treatment framework rather than creation of a different tadalafil molecule.
No. Twenty milligrams describes the amount of tadalafil in a tablet and does not by itself establish the brand. Other tadalafil tablet products can also contain 20 mg.
No. PAH belongs to specific tadalafil product contexts such as Adcirca and Tadliq, while other tadalafil products are labeled for ED, BPH or combined ED/BPH.
No. Current Adcirca labeling uses a once-daily PAH framework rather than an as-needed treatment strategy.
Current Adcirca labeling advises avoiding concomitant use with Cialis or other PDE5 inhibitors. Cialis and Adcirca both contain tadalafil, so they should not be viewed as unrelated active drugs.
No. Current Adcirca labeling contraindicates concomitant organic nitrate use because tadalafil can potentiate nitrate-associated blood-pressure lowering.
No. Current labeling contraindicates guanylate-cyclase stimulators such as riociguat with tadalafil because of the risk of excessive hypotensive effects.
The core active-drug mechanism comes from tadalafil and involves PDE5 inhibition. What differs is the clinical and tissue context in which that pharmacology is used.
No. Both contain tadalafil and are labeled in the PAH context, but Adcirca is a tablet product while Tadliq is a separate tadalafil oral suspension product.
No. Adcirca is a proprietary brand name. Tadalafil is the established active-drug name used across multiple products.